Heloisa Prado Soares MD
Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology
Associate Professor
Join to View Full Profile
2000 Circle of Hope DrSalt Lake City, UT 84112
Phone+1 801-646-4016
Fax+1 801-585-0124
Dr. Soares is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 2007 - 2010
OtherClass of 2002
Certifications & Licensure
UT State Medical License 2019 - 2026
ID State Medical License 2021 - 2025
MT State Medical License 2021 - 2025
WY State Medical License 2021 - 2025
NV State Medical License 2021 - 2023
CA State Medical License 2010 - 2021
FL State Medical License 2015 - 2021- Join now to see all
Awards, Honors, & Recognition
- Society of Huntsman Translational Scholars Hunstman Cancer Institute at University of Utah, 2024
- Hematology and Medical Oncology Fellowship Faculty Teaching Award Huntsman Cancer Institute at University of Utah, 2021
- “40 Under 40 in Cancer” award The Lynx Group™ and McGivney Global Advisors, 2018
- Join now to see all
Clinical Trials
- Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Start of enrollment: 2022 Mar 24
Roles: Contact
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Roles: Contact, Principal Investigator
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 May 05
- Join now to see all
Publications & Presentations
PubMed
- Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.John R Lozada, Andrew Elliott, Mark G Evans, James Wacker, Kathleen M Storey
Cancer Research Communications. 2025-02-01 - 1 citationsKRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.Carter Norton, Matthew Steven Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P Soares
JAMA Network Open. 2025-01-02 - 1 citationsBilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.Vaibhav Sahai, Kent A Griffith, Bruce S Lin, Heloisa P Soares, Sreenivasa R Chandana
Med. 2024-12-18
Press Mentions
KRAS Mutations Linked to Varied Treatment Outcomes in Metastatic Pancreatic CancerJanuary 9th, 2025- The Society of Huntsman Translational Scholars Welcomes Two More MembersAugust 12th, 2024
- Strategy 2025 Update: Directed Steps for University of Utah Health and Our CommunityMarch 1st, 2023
- Join now to see all
Grant Support
- Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site ApplicationUNIVERSITY OF UTAH2024–2026
Professional Memberships
- Member
Other Languages
- Spanish, Portuguese
External Links
- Linkedinhttps://www.linkedin.com/in/heloisa-soares-gi-oncology
- University of Utahhttps://healthcare.utah.edu/fad/mddetail.php?physicianID=u6026577&name=heloisa-p-soares
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
